Compositions and methods for treating proliferative disorders such as NK-type LDGL

Details for Australian Patent Application No. 2005238300 (hide)

Owner Universita Di Genova Innate Pharma

Inventors Moretta, Alessandro; Romagne, Francois

Agent Pizzeys

Pub. Number AU-A-2005238300

PCT Pub. Number WO2005/105849

Priority 60/567,329 30.04.04 US

Filing date 29 April 2005

Wipo publication date 10 November 2005

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

Event Publications

23 November 2006 PCT application entered the National Phase

  PCT publication WO2005/105849 Priority application(s): WO2005/105849

25 November 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005238308-Methods for reducing or eliminating alpha-mannosidase resistant glycans in the production of glycoproteins

2005238298-Compositions and methods for enhancing NK cell activity